巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Arvinas

    ARVN
    57.900
    2.100
    3.76%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Arvinas - 延遲價格・最後更新於 10/08 9:30
    最高位
    58.530
    最低位
    56.600
    開市價
    --
    前收市價
    55.800
    成交量(千)
    14.18
    成交額(百萬)
    7.40
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    3,080.59
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    98.670 - 34.900
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Arvinas
    證券代碼
    ARVN.US
    所屬板塊
    Biotechnology
    公司業務
    Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
    發行量
    53165962
    公司總部
    395 Winchester Avenue, 5 Science Park
    公司網址
    https://www.arvinas.com
    公司電郵
    ir@arvinas.com
    公司電話
    +1 203 535-1456
    暫無內容

    關於

    Arvinas(ARVN.US)所屬的行業板塊為Biotechnology。
    Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
    詳細公司背景可參考: https://www.arvinas.com